Despite an FDA approval of growth hormone treatment for children with idiopathic short stature (ISS), the mean cost burden to patients and their families has increased over time.
from EurekAlert! - Breaking News https://ift.tt/2JFeANw
via IFTTT
Monday, March 25, 2019
Patients bear increased financial burden for growth hormone treatment despite FDA approval
About Admin -
Author Description here.. Nulla sagittis convallis. Curabitur consequat. Quisque metus enim, venenatis fermentum, mollis in, porta et, nibh. Duis vulputate elit in elit. Mauris dictum libero id justo.